Retatrutide vs Tirzepatide Vial Size Comparison

A retatrutide vs tirzepatide vial size comparison usually starts with a mismatch: listings for the two compounds rarely use the same milligram increments, which makes a plain price-per-vial comparison misleading unless the numbers are normalized to a common unit first.

Why the Two Compounds Are Sized Differently

Retatrutide and tirzepatide are distinct peptide chains with different molecular weights and different histories in the research supply market. Retatrutide listings commonly appear in 5 mg, 10 mg, 15 mg, and 20 mg vials, while tirzepatide listings more often cluster around 5 mg, 10 mg, 15 mg, and 30 mg. Neither spacing is a regulatory standard — each supplier chooses vial sizes based on how they source bulk lyophilized powder and how they expect buyers to reconstitute it. That means a “10 mg vial” from one supplier and a “10 mg vial” from another should contain the same mass of peptide, but the surrounding packaging, diluent recommendations, and pricing tiers can still vary.

The practical effect is that a shopper comparing retatrutide vs tirzepatide vial size options is not comparing two versions of the same catalog. They are comparing two separate product lines that happen to occupy the same general dose range.

Reading a Listing Correctly

A vial label or product listing typically states total peptide mass per vial, not concentration. Concentration only exists after reconstitution, when a fixed mass of lyophilized powder is dissolved into a chosen volume of bacteriostatic water. This is the detail that trips up most side-by-side comparisons: two vials with identical mg totals can produce very different concentrations depending on how much diluent is added.

The formula is straightforward:

Concentration (mg/mL) = vial mg ÷ mL of bacteriostatic water added

Worked Example

Take a 10 mg retatrutide vial and a 10 mg tirzepatide vial, both reconstituted with 2 mL of bacteriostatic water.

Concentration = 10 mg ÷ 2 mL = 5 mg/mL for both.

On a U-100 insulin syringe, where 1 mL equals 100 units, that 5 mg/mL solution means each unit drawn on the syringe corresponds to 0.05 mg (5 mg ÷ 100 units), or 50 mcg per unit, since 1 mg equals 1000 mcg.

Now compare that to a 15 mg vial of either compound reconstituted with the same 2 mL:

Concentration = 15 mg ÷ 2 mL = 7.5 mg/mL, or 75 mcg per unit on a U-100 syringe.

This is why vial size alone does not tell the full story. Two vials labeled with different mg totals can be reconstituted to match the same concentration by adjusting diluent volume, and two vials with the same mg total can be turned into different concentrations the same way. Anyone working through this kind of reconstitution math by hand can cross-check the arithmetic against a dedicated tool like the reconstitution calculator at peptcalc.com before finalizing any figures.

Vial Size Comparison Table

Vial Size	Common In	Typical Diluent Range	Resulting Concentration Range
5 mg	Retatrutide, Tirzepatide	1-2 mL	2.5-5 mg/mL
10 mg	Retatrutide, Tirzepatide	1-2 mL	5-10 mg/mL
15 mg	Retatrutide, Tirzepatide	1-3 mL	5-15 mg/mL
20 mg	Retatrutide (less common in tirzepatide lines)	2-4 mL	5-10 mg/mL
30 mg	Tirzepatide (less common in retatrutide lines)	2-4 mL	7.5-15 mg/mL

The ranges above reflect what listings and reconstitution guides commonly describe, not a fixed rule — the actual diluent volume chosen determines the final concentration for any vial size.

Why Vial Size Affects Cost-Per-Milligram Math

Because retatrutide and tirzepatide vials are not sized identically across the market, comparing sticker price alone produces a distorted picture. A 20 mg retatrutide vial priced higher than a 10 mg tirzepatide vial is not necessarily more expensive on a per-mg basis — it depends entirely on dividing total price by total mg content, not by vial count. This is the same normalization principle that applies within a single compound’s product line, where larger vials often carry a lower per-mg price than smaller ones due to fixed packaging and handling costs being spread across more peptide mass.

Buyers who want a reliable retatrutide vs tirzepatide vial size comparison should build a simple table: vial size, listed price, and price divided by mg. That third column is the only number that allows a fair comparison across compounds and across suppliers, since it strips out the arbitrary choice of vial size entirely.

Sourcing Considerations Beyond Vial Size

Vial size and concentration math only matter if the underlying product matches its label. Listings that pair clear mg totals with an accompanying certificate of analysis make it easier to confirm that a “10 mg” vial actually contains 10 mg of the stated peptide before any reconstitution math is applied. Cross-referencing a listing against a this retatrutide listing is one of the more direct ways to confirm that the vial size stated on a label matches what independent testing found in the vial.

Researchers comparing catalogs across multiple sites often find it useful to check how other trackers in this space break down vial economics — for example, peer retatrutide listing catalogs cover retatrutide-specific listing trends and track a broader set of GLP-based research compounds side by side.

Summary

Retatrutide and tirzepatide vials are rarely sized identically across suppliers, which means a raw comparison of vial size or sticker price does not reveal much on its own. The more reliable comparison converts every vial to a concentration figure after reconstitution and a cost-per-milligram figure before any purchase decision, treating vial size as one input to that math rather than the answer itself.